Please use this identifier to cite or link to this item:
|Title:||Correspondence between alpha-particle emitter dosimetry and normal organ toxicity|
|Authors:||JOSEFSSON ANDERS; NEDROW JESSIE; HOBBS ROBERT F.; BAECK TOM; PARK SUNJU; BRUCHERTSEIFER FRANK; MORGENSTERN ALFRED; SGOUROS GEORGE|
|Publisher:||European commision - Joint Research Centre|
|Type:||Articles in periodicals and books|
|Abstract:||The objective of dosimetry is to guide the design and implementation of radiopharmaceutical therapy, either on a patient population basis, or if the variability is sufficiently high, on an individual patient basis. Key to this is that absorbed dose estimates predict likely toxicity and tumor response to treatment. It is not possible to administer a tracer level of activity in alpha-particle emitter therapy to obtain the pharmacokinetics required for dosimetry, therefore, preclinical microscale dosimetry studies must be combined with macroscopic whole-organ dosimetry. We illustrate this approach for an antibody that targets the immune checkpoint inhibitor, PD-L1 which we have investigated as a means of alpha-particle emitter delivery in a combined immunological and alpha-particle emitter targeting strategy.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.